ReviewExpert opinion on drug safety2013
Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management.
Review in Expert opinion on drug safety, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.Obesity (Silver Spring, Md.) · 2026Pooled it
- Advances in pharmacologic management of obesity: oral semaglutide for weight management.Annals of medicine and surgery (2012) · 2026Article
- Combination Pharmacotherapies for Obesity-Current Evidence and Future Directions.Endocrinology, diabetes & metabolism · 2026Review
- When Side Effects Become Therapies: A Mechanistic Taxonomy of Adverse Drug Reactions as Translational Signals for Drug Repositioning.Fundamental & clinical pharmacology · 2026Review
- Addressing the challenge of obesity in primary care: a review of effective interventions and implementation strategies.Diabetology & metabolic syndrome · 2025Review
- Strengths and Limitations of BMI in the Diagnosis of Obesity: What is the Path Forward?Current obesity reports · 2024Review
- Catalytic intramolecular aminoarylation of unactivated alkenes with aryl sulfonamides.Chemical science · 2022Article
- Weight maintenance: challenges, tools and strategies for primary care physicians.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2016Review
- 2014 EASO Position Statement on the Use of Anti-Obesity Drugs.Obesity facts · 2015Article
- Amphetamine-Like Analogues in Diabetes: Speeding towards Ketogenesis.Case reports in endocrinology · 2015Article
- Tolerability and safety of the new anti-obesity medications.Drug safety · 2014Review
- The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity.Obesity (Silver Spring, Md.) · 2014Article
- The next generation of obesity treatments: beyond suppressing appetite.Frontiers in psychology · 2013Article
- New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical EndocrinologistsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWeight-management options include lifestyle modifications, bariatric surgery and, until recently, limited pharmacotherapy. Phentermine and topiramate extended-release (phentermine/topiramate ER) has recently been approved in the USA for chronic weight management in obese adults and overweight adults with weight-related co-morbidities in conjunction with a reduced-calorie diet and increased physical activity. AREAS COVERED: This review describes the pharmacology and clinical trials data for phentermine/topiramate ER and its role in a complications-centric approach to medical care of the overweight and obese patient. EXPERT OPINION: Phentermine/topiramate ER is an effective and safe weight-loss medication that can produce and sustain approximately 10% loss of body weight. This is a landmark development in the pharmacotherapy of obesity. By offering an effective medical option to complement lifestyle and surgical approaches, phentermine/topiramate ER enables a comprehensive medical model for obesity care. The overall approach to the overweight and obese patient should be to identify individuals who will benefit most from therapy based on cardiometabolic or mechanical complications, establish therapeutic targets and goals for ameliorating these complications and selecting the treatment modality and intensity for weight loss to achieve these goals. This complications-centric model emphasizes weight loss as a tool to ameliorate obesity-related complications and optimizes benefit/risk for achieving the best outcomes in overweight/obese patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.